Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study

Richard T. Maziarz(Oregon Health & Science University), Marcie Riches(Medical College of Wisconsin), Juan Gea‐Banacloche(National Institutes of Health), Vijay Reddy(University of Florida), B Geroge(Christian Medical College, Vellore), Michael Boeckh(Fred Hutch Cancer Center), M Chen(Medical College of Wisconsin), Christopher C. Dvorak(University of California, San Francisco), Caroline A. Lindemans(University Medical Center Utrecht), Eva C. Guinan(Dana-Farber Cancer Institute), Ruta Brazauskas(Medical College of Wisconsin), Minoo Battiwalla(Sarah Cannon), Lynne Strasfeld(CancerCare Manitoba), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Jeffery J. Auletta(Nationwide Children's Hospital), Bipin N. Savani(Vanderbilt University Medical Center), Muthalagu Ramanathan(UMass Memorial Health Care), J. W. Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Franklin O. Smith(Cincinnati Children's Hospital Medical Center), J L Liesveld(University of Rochester Medicine), Randy Taplitz(CancerCare Manitoba), Aleksandra McLeod(Oregon Health & Science University), Gregory A. Hale(Johns Hopkins University), John R. Wingard(University of Florida Health), H M Lazarus(University Hospitals Cleveland Medical Center), Rodrigo Martino(Universitat Autònoma de Barcelona)
Bone Marrow Transplantation
December 19, 2016
Cited by 40


Related Papers